iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum

DELAWARE, March, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has been invited to present at the Mid-Atlantic Diamond Venture (MADV) Virtual Spring Forum on Friday, March 25, 2022.

Dedicated to improving the management of neuropathic pain, iQure developed iQ‑007 as a promising candidate with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with encouraging results in both neuropathic pain as well as epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a better-than-standard profile in all tested in vivo pain models.

“We are delighted to have been invited to present at this high-profile event,” said iQure Chief Executive Officer, Pawel Zolnierczyk. “This presentation helps to expand our network to an even larger group of investors from the Mid-Atlantic region and enhances our company’s ongoing fund-raising efforts.”

Mid-Atlantic Diamond Ventures (MADV) is an independent organization that assists emerging, technology-based companies in their effort to build sustainable businesses by better positioning them for funding while increasing value at an early and crucial stage.

To date, over 400 Mid-Atlantic companies have presented at MADV and have raised more than $640 million. MADV is located at the Temple University Fox School of Business and is sponsored by prestigious service firms, major angel constituencies, as well as, local economic development groups.

iQure Pharma is Investment-Ready — Will Present at Keiretsu Forum Mid-Atlantic

DELAWARE, February 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has completed its Due Diligence process with Keiretsu Mid-Atlantic as Lead Investors, with initial commitments already secured.

Dedicated to a new generation of neuropathic pain management therapeutics, iQure developed iQ-007 as a promising candidate with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with encouraging results in neuropathic pain as well as a secondary indication of epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a better-than-standard profile in all tested in vivo pain models.

“We are delighted to have the opportunity to provide an update to the Keiretsu Mid-Atlantic and South-East Chapters,” said iQure Chief Executive Officer, Pawel Zolnierczyk. "This update helps to arrange the funding required to reach the clinical stage, which will offer alternative treatment options to a large number of patients suffering from Neuropathic Pain.”

The Due Diligence process was completed successfully, and the company is now fully prepared to accept funding from investors, while offering attractive investment terms. The Angel Investor-friendly Term Sheet for Series A Preferred offers capital protection, favorable valuation, and a significant number of warrants. Company is in the process of securing $3.9MM and first commitments have already been received from members of the Due Diligence Team.

iQure Pharma Awarded Patent for Therapy to Treat Neuropathic Pain and Epilepsy

DELAWARE, January 12, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a patent for a therapeutic being developed for the treatment of neuropathic pain and epilepsy (iQ-007). In addition, iQure’s multi-targeting compound to treat pain (iQ-008) has entered the national patent stage.

Dedicated to a new generation of neuropathic pain management therapeutics, iQure developed iQ-007 as a new chemical entity with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with promising results in the secondary indication of epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a promising profile in all in vivo pain models.

“We are delighted with this first patent granted for iQ-007,” said iQure Chief Executive Officer Pawel Zolnierczyk. “This crucial step in the process of developing a new treatment helps to build awareness about the importance of therapies for neuropathic pain. One of the limiting factors in epilepsy and pain management treatments, like drug-resistant epilepsy, childhood epilepsy and painful diabetic peripheral neuropathy, are the debilitating central side effects limiting use in the current standard of care. Our goal is to bring relief to those populations.”

Recent experiments confirmed that iQ-007 acts as a positive allosteric modulator of naturally occurring neuromodulator EAAT2. Through this unique mechanism, it enhances the natural glutamate uptake preventing neurotoxicity often associated with epilepsy and neuropathic pain. iQ-007 has already been granted formal confirmation of patent protection by the Polish patent office.

With iQ-008 showing efficacy in outperforming standards of care, iQure is securing global protection, including the US, Europe, China and Canada. For both assets, iQure’s patents focus on composition of matter claims and medical use in neurological disorders.